Research programme: cardiovascular disorder therapeutic - Penwest PharmaceuticalsAlternative Names: PW4105
Latest Information Update: 20 Aug 2009
At a glance
- Originator Penwest Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 17 Oct 2003 Preclinical trials in Cardiovascular disorders in USA (unspecified route)